The Vanguard Group Discloses Position in Avadel Pharmaceuticals

The Vanguard Group, Inc. has released its Form 8.3, providing detailed disclosure related to its stake in Avadel Pharmaceuticals plc. The disclosure, dated January 26, 2026, reveals Vanguard's interest in US$0.01 ordinary shares of Avadel, holding 5,865,178 shares, representing 6.02% of the relevant securities.

The report is necessitated under Rule 8.3 of the Irish Takeover Panel Act, 1997, which requires stakeholders with interests exceeding 1% to declare their positions. In this case, Vanguard's disclosure falls in line with these requirements, maintaining transparency in dealings involving Avadel Pharmaceuticals.

Vanguard also discloses a recent purchase of 3,352 shares at a price of 21.57 USD per unit. No derivative transactions or other agreements have been noted. As of the report, there are no indemnity or dealing arrangements related to Avadel's securities in place.